易瑞生物(300942) - 2025年4月27日投资者关系活动记录表

Group 1: Partnership Overview - The partnership with Chr.Hansen A/S (referred to as "Chr.Hansen") is significant as it is a global provider of biological solutions, particularly in the food and nutrition sectors [3] - Chr.Hansen merged with Novozymes A/S to form Novonesis, enhancing their capabilities in biological solutions [3] - Novonesis reported a revenue of approximately RMB 31.5 billion and a net profit of about RMB 2.5 billion in 2024 [3] Group 2: Financial Impact - The sales target for the partnership from 2025 to 2029 is set at €73.06 million, equivalent to approximately RMB 600.83 million, with 2025 accounting for about 42.18% of the company's audited revenue for 2024 [4] - Historical transaction amounts with Chr.Hansen were RMB 4.23 million, RMB 31.35 million, and RMB 31.43 million for the years 2022, 2023, and 2024, respectively, representing 0.62%, 12.34%, and 14.02% of the company's annual revenue [10] Group 3: Strategic Advantages - The collaboration allows for exclusive sales and distribution rights in specified regions, excluding China and a few other countries, enhancing market penetration [4] - The dual branding strategy ("BioEasy & Chr.Hansen") on product packaging is expected to strengthen both companies' market presence [4] - The partnership is anticipated to facilitate entry into new markets and diversify the company's offerings in various sectors, including veterinary medicine and agricultural testing [5][6] Group 4: Future Development Strategy - The company aims to focus on steady growth in food safety testing and expand its animal diagnostics business [7] - Plans include strengthening domestic market presence while leveraging international partnerships to enhance global market share [8] - The company intends to build a diversified customer base, targeting both government and enterprise clients in the food production sector [12][13] Group 5: Profitability Insights - The high gross margin in overseas product sales is attributed to the proprietary production of antibodies, which are crucial for food safety testing [9] - The overseas market is expected to yield higher profit margins due to lower price sensitivity [9]